Paladin Labs announces the acquisition of Triton Pharma, effective from January 1, 2014. Triton is a privately-held, Canadian pharmaceutical company focused on acquiring and in-licensing specialty prescription products.
Its portfolio of products spans across women’s health, urology and dermatology. Under the agreement, Paladin expects Triton to contribute sales of approximately $4 million in 2014 from its product portfolio. Further details and financial terms of the deal were not disclosed.
“The acquisition of Triton demonstrates our commitment to continue to grow our product portfolio in the Canadian market,” said Mark Beaudet, interim president and CEO of Paladin Labs. “We believe we can be a more efficient operator of the Triton assets and leverage their portfolio of products to greater strategic advantage via our business development activities. In particular, the addition of Triton’s dermatology products will give us critical mass in this interesting niche therapeutic category.”
Quantum Genetix acquires GenServe Laboratories™ Next Post:
Tekmira inks option deal with ag-bio powerhouse Monsanto